Charles Russell Speechlys has advised on a significant investment in the healthcare industry
Charles Russell Speechlys has advised Newmedica on a major investment by Specsavers to create a partnership that will focus on transforming eye health services for patients in the community. With hospital eye departments under pressure due to an ageing population and an increase in treatable eye conditions, the partnership hopes to support the NHS ophthalmology services, with support from their stores.
One of the largest independent clinical ophthalmology service providers in the UK, Newmedica was founded in 2007 to provide eye care services to the NHS. Its philosophy is one of innovation in ophthalmology delivery, changing the way services are delivered to improve clinical quality, patient experience and efficiency. It operates from 25 community and GP sites, NHS and private hospitals and mobile clinics in England. Services delivered cover the full range of ophthalmology, including outpatients and surgery, adult, paediatric and neonatal ophthalmology.
Darshak Shah, co-founder and director of Newmedica, said: “This represents a significant milestone and a hugely positive development for Newmedica, enabling us to develop the business for a long term future in support of our mission of making eye care better. We were extremely grateful to the team at Charles Russell Speechlys for guiding us through the process, especially with their wider healthcare expertise.”
Richard Norton, lead Partner at Charles Russell Speechlys, commented: “We have acted for Newmedica since their incorporation and are pleased to have helped them in the development of their Specsavers partnership. We look forward to the improvements in eye health that the parties are aiming to achieve.”
News & Insights
The Enterprise Investment Scheme : a case study
An example of how even straightforward EIS funding arrangements require professional advice to navigate and solve complexities.
Public Company Update - November 2017
Welcome to the November edition of our biannual Public Company Update.